青光眼与高眼压激光试验(LiGHT):原发性选择性激光小梁成形术对比滴眼液治疗青光眼与高眼压的六年结果
LiGHT 试验是一项前瞻性多中心随机对照试验,比较初始选择性激光小梁成形术(SLT)与降眼压滴眼液治疗未治过的开角型青光眼(OAG)或高眼压(OHT)患眼。6年结果显示两组健康相关生活质量(HRQoL)无显著差异,SLT组青光眼症状量表评分更优,且SLT组疾病进展、小梁切除术和白内障手术均少于滴眼液组。
要点
- 6年时SLT组与滴眼液组在EQ-5D-5L、青光眼效用指数和青光眼生活质量-15上无显著差异(P均>0.05)。
- SLT组青光眼症状量表评分为83.6±18.1,优于滴眼液组的81.3±17.3。
- SLT组69.8%的患眼无需药物或手术即维持目标眼压或以下。
核心结论
- 选择性激光小梁成形术是OAG和OHT的安全治疗方法,在6年内提供比初始滴眼液治疗更好的长期疾病控制,并减少了眼内青光眼手术和白内障手术的需求。
研究设计与样本
- 前瞻性、多中心随机对照试验,纳入未接受过治疗的OAG或OHT患眼,随机分配至初始SLT组或降眼压滴眼液组。
- 在LiGHT试验完成3年的692例患者中,633例(91.5%)进入延伸期,524例完成6年(占进入延伸期的82.8%)。
主要发现
- 6年时,EuroQol EQ-5D 5水平、青光眼效用指数和青光眼生活质量-15均无显著差异(P均>0.05)。
- SLT组青光眼症状量表评分为83.6±18.1,滴眼液组为81.3±17.3(SLT组更优)。
- SLT组69.8%的患眼无需药物或手术治疗即维持目标眼压或以下。
- 滴眼液组疾病进展眼数多于SLT组(26.8% vs 19.6%,P=0.006)。
- 滴眼液组32眼需小梁切除术,SLT组13眼(P<0.001);滴眼液组白内障手术95眼,SLT组57眼(P=0.03)。
关键数值与推荐
- SLT组在初始3年后如必要允许第三次SLT;滴眼液组允许以SLT作为治疗转换或升级。
- 未发生与激光相关的严重不良事件。
临床怎么用
- SLT可作为OAG和OHT的初始治疗选择,6年随访中显示出更好的长期疾病控制并减少手术需求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial has shown selective laser trabeculoplasty (SLT) to be clinically and cost-effective as a primary treatment of open-angle glaucoma (OAG) and ocular hypertension (OHT) at 3 years. This article reports health-related quality of life (HRQoL) and clinical effectiveness of initial treatment with SLT compared with intraocular pressure (IOP)-lowering eye drops after 6 years of treatment. DESIGN: Prospective, multicenter randomized controlled trial. PARTICIPANTS: Treatment-naive eyes with OAG or OHT initially treated with SLT or IOP-lowering drops. METHODS: Patients were allocated randomly to initial SLT or eye drops. After the initial 3 years of the trial, patients in the SLT arm were permitted a third SLT if necessary; patients in the drops arm were allowed SLT as a treatment switch or escalation. This study is registered at controlled-trials.com (identifier, ISRCTN32038223). MAIN OUTCOME MEASURES: The primary outcome was HRQoL at 6 years; secondary outcomes were clinical effectiveness and adverse events. RESULTS: Of the 692 patients completing 3 years in the LiGHT Trial, 633 patients (91.5%) entered the extension, and 524 patients completed 6 years in the trial (82.8% of those entering the extension phase). At 6 years, no significant differences were found for the EuroQol EQ-5D 5 Levels, Glaucoma Utility Index, and Glaucoma Quality of Life-15 (P > 0.05 for all). The SLT arm showed better Glaucoma Symptom Scale scores than the drops arm (83.6 ± 18.1 vs. 81.3 ± 17.3, respectively). Of eyes in the SLT arm, 69.8% remained at or less than the target IOP without the need for medical or surgical treatment. More eyes in the drops arm exhibited disease progression (26.8% vs. 19.6%, respectively; P = 0.006). Trabeculectomy was required in 32 eyes in the drops arm compared with 13 eyes in the SLT arm (P < 0.001); more cataract surgeries occurred in the drops arm (95 compared with 57 eyes; P = 0.03). No serious laser-related adverse events occurred. CONCLUSIONS: Selective laser trabeculoplasty is a safe treatment for OAG and OHT, providing better long-term disease control than initial drop therapy, with reduced need for incisional glaucoma and cataract surgery over 6 years.
引用
- Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial: Six-Year Results of Primary Selective Laser Trabeculoplasty versus Eye Drops for the Treatment of Glaucoma and Ocular Hypertension. Ophthalmology. 2022. PMID: 36122660. doi:10.1016/j.ophtha.2022.09.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。